Oorsprong van het eerstegraads netwerk van Carlos Guillem
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
Renibus Therapeutics, Inc.
 Renibus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Renibus Therapeutics, Inc. engages in manufacture of pharmaceutical products. The company was founded by Donald Jeffrey Keyser and Alvaro F. Guillem in 2015 and is headquartered in Southlake, TX.
3
| Holding Company | Pharmaceuticals: Major | 3 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Carlos Guillem via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| ABBOTT LABORATORIES | Medical Specialties | Corporate Officer/Principal | |
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Encysive Pharmaceuticals, Inc.
 Encysive Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Encysive Pharmaceuticals, Inc. discovers, develops and markets drugs for the treatment of cardiovascular, vascular and related inflammatory diseases. The firm focuses its research and development programs on the treatment and prevention of interrelated diseases of the vascular endothelium, inflammatory cascade and vascular diseases. The company was founded by James T. Willerson in 1989 and is headquartered in Houston, TX. | Pharmaceuticals: Major | Compliance Officer | |
| VERNALIS | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| GENVEC INC | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Alba Therapeutics Corp.
 Alba Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical Company focused on the discovery, development and commercialization of pharmaceutical products to treat autoimmune and inflammatory diseases and is based in Baltimore, Maryland. Genetics, environment, aberrant immune response, and barrier dysfunction are all required for autoimmunity. Alba's technology platform is based on modifying disease state epithelial permeability using compounds which impact the regulation of tight junctions in cell barriers throughout the body with potential applications in celiac disease, Crohn's disease, asthma/COPD and acute lung injury. As a development stage company Alba maximizes value creation by leveraging its human capital, partnerships and technology. Since the Company's formation in 2004, the company has entered human clinical trials with its lead product, received Fast Track designation from the FDA (in Celiac Disease), successfully completed three Phase I clinical trials and completed its first Phase II study. Along with $30m raised in its Series A financing, equity and non-equity capital, such as SBIR and ATP grants and venture debt, are being used to develop products, enhance its powerful IP position and build the Company's infrastructure and core competencies | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| ZS PHARMA INC | Pharmaceuticals: Major | Founder Chief Tech/Sci/R&D Officer | |
| Creighton University | College/University | Graduate Degree | |
| The University of Texas at Dallas | College/University | Doctorate Degree | |
| University of Copenhagen | College/University | Doctorate Degree | |
| Adams Laboratories, Inc. | General Counsel | ||
| Novo-Nordisk Biochem, Inc. | Chief Tech/Sci/R&D Officer | ||
| University of Missouri-Kansas City | College/University | Graduate Degree | |
| Medeva Americas, Inc. | General Counsel | ||
| Nabi Pharmaceuticals | Chief Tech/Sci/R&D Officer | ||
| ALLAKOS INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| Rasmussen Biotech & Pharma Consulting LLC | Chief Executive Officer | ||
| LANTERN PHARMA INC. | Pharmaceuticals: Major | Chairman | |
Neoprogen, Inc.
 Neoprogen, Inc. BiotechnologyHealth Technology Neoprogen, Inc. engages in the development of cell-based therapy for people who experience a heart attack. The company was founded by Sunjay Kaushal, Rachana Mishra and Sudhish Sharma and is headquartered in Baltimore, MD. | Biotechnology | Director/Board Member |
Statistieken
Internationaal
| Verenigde Staten | 22 |
| Verenigd Koninkrijk | 2 |
| Denemarken | 2 |
| Frankrijk | 2 |
Sectoraal
| Health Technology | 14 |
| Consumer Services | 5 |
| Distribution Services | 2 |
| Health Services | 2 |
Operationeel
| Chief Tech/Sci/R&D Officer | 9 |
| General Counsel | 7 |
| Director/Board Member | 6 |
| Corporate Officer/Principal | 5 |
| Founder | 5 |
Sterkste connecties
| Insiders | |
|---|---|
| Henrik Rasmussen | 14 |
| Donald Keyser | 13 |
| Bhupinder Singh | 1 |
- Beurs
- Insiders
- Carlos Guillem
- Bedrijfsconnecties
